Objectives: Rapid diagnosis and appropriate empirical antimicrobial therapy before the availability of conventional microbiological results is of pivotal importance for the clinical outcome of ventilator-associated pneumonia (VAP). We evaluated the VAPChip, a novel, closed cartridge molecular tool aiming to identify directly from clinical samples and within a working day the principal bacteria causative of VAP as well as clinically relevant b-lactam resistance genes.
Introduction
Nosocomial pneumonia, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), represents one of the most important causes of morbidity and mortality, with an attributable mortality rate ranging between 25% and 50%. 1 According to the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), HAP occurs at a rate of 5 -10 cases per 1000 hospital admissions, and with an incidence increasing as much as 5-to 20-fold in mechanically intubated and ventilated patients. 2 The major reason for performing bacterial culture is to optimize anti-infective therapy, which depends on identifying the causative agent of infection in a timely manner and determining its antimicrobial susceptibility profile. The turnaround time using conventional diagnostic methods (ranging from 48 to 96 h for complete testing) is overly long for optimal patient care. 2, 3 With the ever-expanding appearance of multidrug-resistant pathogens, including among others, Pseudomonas aeruginosa, Acinetobacter spp. and Klebsiella pneumoniae, administration of an appropriate empirical anti-infective therapy for bacterial pneumonia early in the onset of VAP/HAP is of crucial importance for a favourable clinical outcome. 4 -8 Molecular amplification methods for rapid diagnosis of respiratory tract infection could improve initial empirical patient care.
The commonly used molecular techniques to detect genes encoding resistance are the nucleic acid amplification methods end-point PCR 9, 10 or real-time PCR. 11 -14 Microarray technology is a tempting approach that simultaneously targets a large panel of genes, and several reports have described bacteria or resistance detection, 15 -17 but only a few systems have been made available for clinical diagnostic use. 18 Today, rapid detection and identification of pathogens can be performed directly from clinical specimens 1,19 -21 by innovative technologies such as PCR-ElectroSpray Ionization MS (PCR/ESI-MS), which relies, however, on the use of an expensive operating system, 22 but which is also able to address the issue of antibiotic resistance. 23 The newly developed Real-time Array-PCR for Infectious Diseases (RAP-ID) technology platform combines the characteristics of real-time PCR with the ability to target simultaneously a wide range of bacterial species and b-lactamases resistance genes using the multiplexing capacity and specificity of microarrays.
The multiplex PCR and hybridization are performed in a single, closed plastic cartridge, thereby eliminating the risks of contamination and offering a simplified workflow. As a result of this unique blend of technologies, the RAP platform is capable of achieving multiplex analysis of 37 targets in about 4 h.
The VAPChip (Eppendorf Array Technologies, Namur, Belgium) is an assay developed along with the RAP-ID technology. The current version of the VAPChip assay targets 13 key bacterial pathogens that are causative of VAP and 24 associated b-lactam resistance traits considered to be of clinical relevance (Figure 1 ). The VAPChip assay is intended for direct use on bronchoalveolar lavage, protected brush specimens and endotracheal aspiration specimens from patients with a suspected diagnosis of VAP or HAP.
The aim of this preliminary study was to evaluate the analytical performance of the VAPChip assay on a collection of representative and genotypically characterized clinical isolates before further evaluation on respiratory tract clinical specimens. RT-PCR array for identification of VAP bacterial pathogens 341 
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Materials and methods
Bacterial isolates
The VAPChip was validated using 292 reference/collection or wellcharacterized isolates, including 225 clinical isolates mostly belonging to one of the targeted pathogens causative of VAP as well as 67 isolates either belonging to species of the commensal oropharyngeal flora or recognized as respiratory pathogens not targeted by the array and/or usually not involved in VAP (Tables 1 and 2 ). Bacterial identification to the species level was carried out using matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry on a Microflex LT (Bruker Daltonics, Leipzig, Germany). The strains were characterized with respect to their b-lactamase genes by PCR amplification and by standard DNA sequencing or with Check-Points microarray systems (Check-MDR CT101, 102 or 103; Check-Points, Wageningen, The Netherlands) according to a protocol already described. 18 In order to challenge the specificity of the assay with respect to the detection of resistance genes, the collection also included wild-type susceptible organisms as well as isolates carrying/expressing resistance genes not targeted by the array.
DNA extraction
The DNA of the clinical isolates was extracted by DNeasy Blood Tissue Kit (Qiagen, Venlo, The Netherlands) at Erasme Hospital and by NucliSENS EasyMAG (bioMérieux, Marne-la Coquette, France) at Mont-Godinne Hospital according to the manufacturers' instructions.
Quantification of the DNA was performed by ultraviolet spectrophotometric measurement of the absorption at 260 nm using the Nanodrop spectrophotometer (Nanodrop, Wilmington, NC, USA). The genome sizes of the different species (ranging from 1.8 to 6.6×10 6 nucleotides for Haemophilus influenzae and Pseudomonas aeruginosa, respectively) were obtained from the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov). An approximated molecular weight of the genome was calculated according to the formula for double-strand DNA: molecular weight of the genome (G/mole)¼genome size (nucleotides)×660, and the number of genome copies per 10 ng of DNA of each species was evaluated accordingly (ranging from 5.2×10 6 to 1.4×10 6 for H. influenzae and P. aeruginosa, respectively).
The RAP-ID platform and the VAPChip assay
The present validation was performed with the VAPChip assay whose composition is shown in Figure 1 . The assay targets 13 VAP-associated pathogens and 24 relevant antimicrobial resistance determinants, including mecA, as well as gene sequences targeting the most commonly encountered extended-spectrum b-lactamases (ESBLs) (TEM, SHV and CTX-M) and carbapenemases (IMP, VIM, KPC and OXA). Specific nucleotide sequences leading to amino acid substitutions responsible for the ESBL phenotype at positions 104, 164, 237, 238, and 240 in TEM-1 and 238 and 240 in SHV-1 are detected by this assay, allowing the straightforward distinction between ESBL and non-ESBL alleles without the need for sequencing ( Figure 1 ). The microarray is composed of specific capture probes corresponding to the targeted bacteria species and their resistance genes, and of capture probe controls. Each capture probe is present in triplicate and located randomly on the array. The primers used for the amplification were labelled with Oyster-650 dye, allowing the detection of the hybridized amplicons on the array. The blind evaluation of the 292 isolates was performed with 10 3 copies of genomic DNA. Non-targeted controls (including both the bacterial isolates and the resistance genes) were further tested at 10 6 copies of genomic DNA in order to assess the specificity of the assay. A 5 mL aliquot of the extracted sample DNA was spiked into the VAPChip cartridge containing all reagents for PCR. The final volume was 110 mL of Mastermix (83 mL) containing 1 U of Supersalt enzyme, the Supersalt PCR buffer with dNTPs at 200 mM each, and the primer mix (22 mL) containing 31 pairs of primers.
Software controls the full process of the cycler parameters, liquid transport, fluorescence detection and data acquisition.
The reading of the array was made just after the annealing phase at cycles 1, 20, 23, 26, 29, 32, 35 and 38. For each of these cycles, an image of the array was captured. The RAP-ID analysis software automatically quantifies the image produced by the RAP instrument and displays the results in the user interface (Figure 2) . The results were presented as target detection or absence of target detection. The full process takes 4 h.
Limit of detection and dynamic range analysis
Ten to 10 7 copies of targets were used for evaluation of the limit of detection and the dynamic range of the array. The limits of detection were determined for each of the targets (species and resistance genes) and were calculated as the lowest copy number detected in 90% of 10 repeats. Regarding resistance genes, the limit of detection refers to the evaluated number of bacterial genomes (see the 'DNA extraction' section above) of the isolates expressing the resistance gene.
The linear dynamic ranges were evaluated within the same dilution range using three collection isolates representing three different bacterial species (P. aeruginosa ATCC 15442, E. coli ATCC 700926 and Staphylococcus aureus ATCC BAA-1556) and repeated five times. In order to increase the precision of the assay, an estimation of the threshold cycle of detection with an accuracy of one cycle instead of three cycles was made by interpolation of the cycle of detection from 20 to 38. The detection cycle values were plotted against the genome copy numbers so as to fit the data to a straight line on the semi-log graph.
The efficiency of the amplification can be calculated based on the slope of the curve, with a slope of 23.32 corresponding to 100% efficiency. 24 Detection of mixed population DNA extracts from different species were also mixed at different concentrations in order to simulate the detection of multiple pathogens in the same sample. Up to five pathogens were mixed at the same concentration (10 3 genomes each) and two different DNA extracts were mixed at different concentrations (10 6 genomes for one pathogen and 10 3 genomes for the second).
Results
Limit of detection and dynamic range
The lowest limit of detection (analytical sensitivity) of the VAPChip assay was 10 copies of genomes in the assay for Acinetobacter baumannii, E. coli and Klebsiella oxytoca, while it corresponded to 100 DNA genome copies for all the other targets (not shown). The targets of the three bacterial species selected to assess the dynamic range of the assay responded linearly (R 2 ¼ 0.945-0.998) as a function of DNA copy number input over five orders of magnitude (10 2 - 10 7 ) with an efficiency ranging between 92% and 108% and a slope of 23.14, 23.22 and 23.54 for P. aeruginosa, S. aureus and E. coli, respectively. All values presented ,10% variations over five repeats, confirming the robustness of the technique (not shown). The assay can thus be considered as linear in the tested range of concentrations, allowing the results to be expressed in a semi-quantitative manner.
Bogaerts et al. a TEM-ESBL, including TEM-24 (n¼15), TEM-52 (n¼5), TEM-10 (n ¼3) and TEM-3 (n¼1); TEM non-ESBL, including TEM wild-type identified by Check-Points (n¼28), TEM-1 (n¼23) and TEM-40 (n ¼1). b SHV-ESBL, including SHV-12 (n¼23), SHV-4 (n ¼6), SHV-2 (n¼3), SHV-5 (n¼2), SHV-2a (n¼2), SHV-18 (n¼1) and SHV-38 (n ¼1); SHV non-ESBL, including SHV-11 (n¼9), SHV wildtype identified by Check-Points (n¼9), SHV-1 (n¼5), SHV-33 (n¼2), SHV-76 (n¼1) and SHV-92 (n¼1). c CTX-M, including CTX-M-9 (n¼13), CTX-M-15 (n¼15), CTX-M-2 (n¼6), CTX-M-3 (n¼3), CTX-M-1 (n¼1), CTX-M-14 (n ¼1) and CTX-M-22 (n¼1). d Carbapenemases, including OXA-23 (n¼7), OXA-58 (n ¼6), OXA-48 (n¼5), VIM-2 (n¼6), VIM-4 (n¼4), KPC-2 (n ¼3), IMP-13 (n¼3), VIM-1 (n¼2), OXA-72 (n¼2) and OXA-40 (n¼1).
e Other VAPChip untargeted/undetected genes encoding resistance, including CMY-2 (n¼11), DHA-1 (n¼3), DHA-7 (n¼1), CMY-10 (n ¼1), ACT-1 (n ¼1), LEN (n¼3), PER-1 (n¼6), BEL-1 (n¼5), GES-11 (n¼2), GES-12 (n¼1), GES-14 (n ¼1), GES-6 (n¼1), GES-1 (n¼1), IMP-4 (n¼1), OXA-10 (n¼2), OXA-1 (n ¼2) and OXA-9 (n¼1). The list of these isolates is presented in Table 2 . k For species identification, sensitivity ¼98.6% and specificity¼100%; for resistance gene identification, sensitivity¼98.7% and specificity ¼97.73%. One SHV-38-producing isolate gave a false-negative result for SHV-ESBL and a false-positive result for SHV non-ESBL.
Analytical performance of the VAPChip (Table 1) Among 292 isolates, 289 (99% agreement) were correctly identified to the species. Global sensitivity for species identification (3 false-negative and 219 true-positive results) was 98.6%. Three of the sample bacteria were not detected [2 E. coli isolates out of 36 (5.5%) and 1 S. aureus isolate out of 14 (7.1%)]. There were no false-positive results (specificity of 100%.) Regarding the detection of the resistance genes, the system presented a global sensitivity and specificity of 98.7% and 97.7%, respectively. The VAPChip did identify correctly the representatives of the three ESBL gene families (bla TEM , bla SHV and bla CTX-M ) tested. The assay was also able to differentiate between non-ESBL and ESBL bla TEM and bla SHV genes and between members of the three major CTX-M groups (CTX-M of group 1, 2 and 9). The agreement of the assay with the reference methods for the detection of bla ESBL genes ranged from 95.8% to 100% depending on the types of ESBL gene families (Table 1) . Only 1 of 24 isolates harbouring a bla TEM-ESBL allele went undetected by the VAPChip (1 E. coli co-expressing TEM-1 and TEM-24 for which the TEM-24 ESBL variant was not detected). Concerning the SHV-ESBL variants, only 1 of the 38 isolates possessing a bla SHV-ESBL resistance gene could not be detected [1 K. pneumoniae isolate with a bla SHV-38 allele that was falsely identified as a non-ESBL variant due to the fact that the VAPChip does not target the bla SHV-38 allele (Ala146Val)].
All 40 isolates carrying bla CTX-M genes were correctly detected by the VAPChip and were also correctly assigned to their different groups (groups 1, 2 and 9).
Regarding the specificity of the assay for the detection of bla ESBL genes, all but 1 of the 79 strains with non-ESBL TEM and SHV alleles were correctly assigned as non-ESBL variants by the VAPChip, except for 1 K. pneumoniae isolate in which the presence of a non-ESBL SHV gene (SHV-11) simultaneously co-expressed with an ESBL variant (SHV-12) went undiagnosed. However, the lack of detection of this non-ESBL SHV variant is unlikely to be of clinical relevance. Noteworthy also was the fact that the different probes did not cross-react with the chromosomally encoded K1 b-lactamase of K. oxytoca (n¼ 15) and LEN b-lactamase of K. pneumoniae (n¼ 3).
With regards to the carbapenemase genes, the VAPChip correctly detected all 39 bla KPC,OXA-23,24/40,48,58,VIM,IMP-13 carbapenemaseproducing isolates as well as the 8 mecA-expressing staphylococcal isolates [S. aureus (n¼ 7) and Staphylococcus epidermidis (n¼ 1)].
Detection of mixed populations
DNA extracts from five different pathogens were mixed at 10 3 genome copies (H. influenzae ATCC 51907D, K. pneumoniae ATCC 700721D-5, P. aeruginosa ATCC 15442, E. coli ATCC 700926 and S. aureus ATCC BAA-1556) were all detected at the Table 2 . Bacterial species and genera belonging to the human oropharyngeal commensal flora and selected potentially pathogenic or opportunistic microorganisms used for the purpose of assessing the specificity of the VAPChip assay same cycle of detection (CD ¼32) (not shown). In addition, when DNA extracts from two different species were mixed and were amplified simultaneously at different concentrations (e.g. P. aeruginosa ATCC 15442 spiked at 10 6 copies and S. aureus ATCC BAA-1556 at 10 3 genome copies), both targets were detected at the two different expected CDs (not shown).
Discussion
The VAPChip assay allows the detection and correct identification of 13 clinically relevant aetiological agents of VAP in addition to 24 important resistance determinants. The assay can be performed in a single working day with both excellent analytical sensitivity and specificity. Overall this assay correctly identified 99% of the 292 isolates by the array, with no cross-reaction being found against a panel of 67 commensals or pathogens that are not (or very unusually) involved in VAP. The two levels of specificity, the primers and the capture probes, explain these good results. The absence of detection in three samples was investigated. For two false-negative E. coli isolates, we found that the bacteria were lacking the targeted uidA (gene encoding glucuronidase) gene. The targeted genes of the undetected S. aureus strain were sequenced and three point mutations were detected in the probe and primer hybridization zones. Additional detection targets/primer and probe sequences for E. coli and S. aureus are currently under validation in order to improve the detection performance for these two species. As the species identification relies on the detection of a single specific and constitutive gene for each species, there is a risk that the natural occurrence of point mutations in the targeted gene may lead to misidentification of some bacterial strains. This point will be more extensively studied during the clinical evaluation of this new tool. The addition or changing of capture probes can be easily done on the array, while the constraints on the changing of primers are much greater given the multiplex PCR. 25 Regarding the selection of species targeted by the array, we decided to include 13 species among those considered as the most frequently responsible of HAP, whether associated with mechanical ventilation and intubation or not. 26 One limitation of the assay in its current format is the absence of certainty of the association of the mecA gene with S. aureus. This may be important in case of the mixed flora of both methicillin-resistant coagulase-negative staphylococci and methicillin-sensitive S. aureus. Addition of the detection of coagulase-negative staphylococci could be particularly useful when mecA is detected in a sample. Detection of coagulase-negative staphylococci species will be performed in the next version of the VAPChip.
Concerning the resistance genes, the VAPChip correctly detected 269 of 272 (98.9%) samples with b-lactam resistance genes (bla TEM , bla SHV , bla CTX-M, carbapenemases and mecA). No cross-reaction was observed between the genes targeted by the array or with any of the naturally present b-lactamase genes of the tested species (e.g. intrinsic bla OXA , chromosomal RT-PCR array for identification of VAP bacterial pathogens bla AmpC and bla K1/OXY ), confirming the excellent specificity of this assay. Only two ESBL-carrying Enterobacteriaceae isolates (one TEM-24 and one SHV-38) went undetected or were erroneously identified as a non-ESBL TEM variant. The SHV-38 b-lactamase is a chromosomally encoded ESBL enzyme (group 2be) that was only rarely reported among clinical isolates. 27, 28 Furthermore, the fact that different species could be mixed in the same sample with multiple resistance traits and the species were correctly identified whatever the species or the genetic background of the tested isolates (presence of multiple resistance genes) confirms that the RAP-ID technology is a promising tool for concomitant species identification and for the detection of coexistent b-lactamase genes. Nevertheless, emerging resistance genes, such as that encoding the New Delhi b-lactamase (NDM), which was not yet reported at the time of the development of the array, should be advantageously integrated in the final commercial version of the product along with additional IMP variants.
The VAPChip in its final format aims to work directly on clinical specimens, which may provide extra value in terms of diagnostic performance and turnaround time in comparison with conventional culture-based methods. The real turnaround time and feasibility of usage of the assay will be challenged during the preclinical and clinical evaluation phases. It will include 4 h for running the PCR itself, in addition to the extraction time for the clinical sample. Ideally the final results (for a maximum of eight samples) should be obtained in the same day. The preliminary results obtained on successive dilutions of a known number of genome copies yielded a limit of detection ranging between 10 and 10 2 copies/PCR and a dynamic range ranging between 10 2 and 10 7 copies, which could allow at least a semiquantitative estimation of the pathogens detected. Eventually the VAPChip assay will have to be validated directly on clinical specimens (bronchoalveolar lavage, protected brush specimens and endotracheal aspiration specimens), and it will be of the utmost importance to define and optimize the cut-off values that allow colonization and infection status to be distinguished. The exact positioning of this detection method in the diagnostic algorithm of HAP/VAP remains to be defined in the setting of a clinical validation process. This step will also be of particular importance in order to assess the potential clinical utility of the test and its best usage by clinicians (i.e. positive diagnostic tool versus rapid exclusion of specific pathogens with rapid subsequent adaptation of empirical therapy). In conclusion, the VAPChip system has proved to be sensitive and specific in detecting clinical bacterial isolates involved in VAP/HAP and it advantageously combines bacterial identification and resistance trait determination.
